Multiple Sclerosis

Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity
Inebriation Remedy And Breakthrough MS Treatment: Meet FSD Pharma
Autism Therapy: Cannformatics Targets Metabolic Imbalances Using Machine Learning
Inebriation Remedy And Breakthrough MS Treatment: Meet FSD Pharma
Autism Therapy: Cannformatics Targets Metabolic Imbalances Using Machine Learning
Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity
Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed

Multiple Sclerosis Recent News

EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS).
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlemen
DEA Sued By Rhode Island Lab Over 'Foot Dragging' On Marijuana Pharmaceutical Licensing, Here's What We Know So Far
Two Rhode Island cannabinoid research laboratories are suing the DEA for standing in the way of what they consider to be the crucial development of pharmaceutical-grade cannabis products for use in clinical trials for the treatment of Multiple Sclerosis and Huntington's Disease. 
Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis
Michigan's JARS Cannabis And Others Join Forces To Raise Awareness During MS Awareness Month
A study funded by the National MS Society recently discovered that nearly one million people are living with Multiple Sclerosis (M
EXCLUSIVE: Pasithea Therapeutics Starts New Multiple Sclerosis Vaccine Development Program
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced a new chemical entity (NCE) development program and named Massachusetts-based Hooke Laboratories as its research partner.
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, 
Europe OKs Biogen's Vumerity For Multiple Sclerosis
Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial?
AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to lack of efficacy in a late-stage trial.
Clene's Stock Gain As Its Nanotherapeutic Improves Energy Production, Brain Utilization In Patients With Parkinson's, Multiple Sclerosis
Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate
Eli Lilly, Verge Genomics Ink $720M Pact For Amyotrophic Lateral Sclerosis Therapies
Europe Approves Sanofi's Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis
Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In Europe
Tiziana Life Starts Testing Nasally Administered Foralumab in Multiple Sclerosis Patients
Janssen's Multiple Sclerosis Treatment Scores European Approval
Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis
Project Twenty 21 Releases Findings: Cannabis Dramatically Improves Lives Of Patients With Debilitating Conditions
Project Twenty 21 has published its first findings in the accredited scientific journal Psychopharmacology. The project, poised to provide patients access to affordable medical cannabis treatment, was launched in 2019 at the Royal College of Psychiatrists in London.
Orphazyme Shares Plummet As Arimoclomol Flunks In Amyotrophic Lateral Sclerosis Study
Tiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab
The FDA has allowed evaluation of Tiziana Life Sciences Plc's (NASDA
Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis
BrainStorm Cell Stock Surges As NurOwn Aces Mid-Stage Multiple Sclerosis Study
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) has